Objective: To determine prognostic value of acoustic rhinometry in patients with perennial allergic rhinitis (PAR) treated with montelukast in fix combination with desloratidine and to assess effectiveness of this medication on health-related quality of life (HRQL). Study design: A randomized, double-blind, prospective and multicentric clinical study. Setting: Tertiary university hospitals. Methods: Patients 20 years of age and older with PAR were assessed over 3 months of treatment with fix combination of montelukast 10 mg plus desloratidine 5 mg once daily (n ¼ 40). Comparative acoustic rhinometric evaluation was used to compare nasal changes in before and after treatments. For evaluation of HRQL between before and after treatments at the first and third months, the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was used. Results: Nasal symptoms and findings including itching, sneezing, discharge, congestion and edema and color change of turbinates have been decreased after treatment. In acoustic rhinometry, minimum cross-sectional area (MCA) measurements and volume results were statistically higher than in before treatment (P , 0.001). Correlation was found that between the volume results and nasal discharged and/or congestion in right nasal passages. In left nasal passages, statistical relation was described between the MCA measurements and itching and/or change of turbinate color (P , 0.05). There was a larger decrease in the overall RQLQ score for the group using montelukast plus desloratidine compared with the pre-treatment scores (P , 0.001). The difference between scores at baseline versus the end of the first and third months for all domains was statically significant (P , 0.001). The treatment difference in change from first month to the end of the third month was statically significant, in favor of the third month, for eye, nose, and non-nose/eye symptoms, sleep, practical problems, emotions and activities that have been limited by nose or eye symptoms, and for overall score. Conclusions: Significant reductions in signs and symptoms of PAR with montelukast plus desloratadine treatment were accompanied by improved disease-specific QOL measures. Montelukast in combination with desloratidine provides improvements in acoustic rhinometric values including volume and MCA in patients with PAR. Acoustic rhinometry should be use in diagnostic and prognostic process in patients with PAR.
ALLERGIES IN OTHER DISEASES

HLA-B58 Does not Increase Allopurinol Hypersensitivity among Patients with Hematologic Malignancy
Jae-Woo Jung, Min-Hye Kim, Woo-Jung Song, Tae-Wan Kim, So-Hee Lee, Sae-Hoon Kim, Hye-Ryun Kang, Heung-Woo Park, Sun-Sin Kim, Yoon-Seok Chang, MD, PhD, Sang-Heon Cho, and Kyung-Up Min. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. Background: HLA-B58 is a very strong marker of allopurinol-induced severe cutaneous adverse reactions (SCARs), especially in population with high frequency of HLA-B58, such as Chinese, Thai, and Korean. Although allopurinol is frequently prescribed to patients receiving chemotherapy for the prevention of tumor lysis syndrome, the risk of allopurinol-related SCARs in patients with hematologic malignancies is not evaluated. This study was conducted to find out the incidence of allopurinol-induced hypersensitivity in patients with hematologic malignancy during chemotherapy according to HLA-B58 and clinical usefulness of HLA-B58 as a risk marker for the development of allopurinol-induced hypersensitivity. Methods: We retrospectively reviewed the medical records of patients with hematologic malignancy who ever took allopurinol and underwent serologic HLA typing for bone marrow transplantation from January 2000 to May 2010. Results: Among total 463 patients, 13 (2.8%) patients experienced allopurinol hypersensitivity reactions which were simple maculopapular rash and none of those were compatible with SCARs. The mean duration of allopurinol exposure in total patients was 26.46 days (1w2,173) and the mean duration until development of rash was 5.54 6 1.20 days. Fifty patients (10.8%) had HLA-B58. However, the incidence of allopurinol induced rash was not different according to HLA-B58 (4% (2/50) and 2.66% (11/413) in B58 (1) and B58 (-) patients, respectively). Frequency of B58 was slightly higher in patients with rash (15.4%) compared with tolerant patients (10.7%) but the difference was statistically insignificant (P . 0.05).
Conclusions:
The results of this study that HLA-B58 does not increase the risk of allopurinol induced SCARs as well as simple rash among patients with hematologic malignancy. Allopurinol can be used safely in most patients with hematologic malignancy during chemotherapy and HLA typing does not give additional advantage for clinical decision.
Risk Factors Associated to Mortality in Pediatric Patients with Hemophagocytic Lymphohistiocytosis
Armando Partida-Gaytan, MD, 1 Blanca del Rio, MD, 1 Gabriela Tercero-Quintanilla, PhD, 2 and Miguel Angel Rosas-Vargas, MD 1 . 1 Pediatric Allergy and Clinical Immunology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico; 2 Psychiatry and Adolescent Medicine, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico. Objective: Identify risk factors associated to mortality in pediatric patients with hemophagocytic lymphohistiocytosis. Methods: Retrospective cross-sectional study of medical records with discharge diagnosis of Hemophagocytic syndrome/Hemophagocytic lymphohistiocytosis (ICD-10; D76.1/D76.2) from Jan2004-May2011 in a pediatrictertiary-care-center. Descriptive and risk analysis were made on SPSS Statistics V17.0. Results: Thirty medical records were analyzed. Median-for-age: 2 years 8 months, (range: 2 months-to-15 years). Sex distribution: 14 girls (47%), 16 boys (53%). Median of symptoms duration: 1 month (range: 3 days-to-7 years). Reported symptoms and physical signs at hospital admission: fever n ¼ 28 (93%), asthenia/adynamia n ¼ 11 (37%), skin findings n ¼ 10 (33%), epistaxis n ¼ 5 (17%), gastrointestinal bleeding n ¼ 4 (13%), hepatomegaly n ¼ 27 (90%), splenomegaly n ¼ 21 (70%), lymphadenopathies n ¼ 14 (47%), paleness n ¼ 14 (47%), purpura n ¼ 5 (17%). Laboratory findings: anemia n ¼ 29 (97%), LDH elevation n ¼ 28 (93%), hypoalbuminemia n ¼ 27 (90%), thrombocytopenia n ¼ 26 (87%), hypertransaminasemia n ¼ 25 (83%), haemophagocytosis n ¼ 22 (73%), hypertrigliceridemia n ¼ 21 (70%), hypofibrinogenemia n ¼ 20 (67%), leucopenia n ¼ 19 (63%), hyperferritinemia n ¼ 15 (50%). In 18 patients (60%) active infection was evident at hospital admission: pneumonia n ¼ 9(50%), gastroenteritis n ¼ 2 (11%), meningitis n ¼ 1 (5%), others n ¼ 6 (33%). Epstein-Barr virus infection was diagnosed in 7 patients (23%). All patients were treated according to HLH-2004 guidelines.
Overall mortality 63% (n ¼ 19), 9(47%) died from septic-shock, 7 (36%) haemorraghic-shock, and 1(5%) with acute liver failure. Differences between non-survivours and survivours by (x 2 ): hypofibrinogenemia (53%versus 13%; P ¼ 0.039), epistaxis (17% versus 0%; P ¼ 0.023), evident clinical infection (47%versus 13%; P ¼ 0.044), elevated LDH levels (63% versus 30%; P ¼ 0.039), hemophagocytosis (57% versus 17%; P ¼ 0.024). Risk factors associated to mortality: history of epistaxis (OR ¼ 1.78, 95% CI, 1.26-2.52; P ¼ 0.023), evident clinical infection at hospital admission (OR ¼ 2.41, 95% CI, 1.08-5.8; P ¼ 0.044). Normal levels of LDH showed diminished mortality risk (OR ¼ 0.32, 95%, CI, 0.18-0.55; P ¼ 0.039). Conclusions: The present study describes the most common clinical, physical and laboratory findings in patients with haemophagocytic lymphohistiocytosis attended in our hospital. We were able to identify risk factors associated to mortality, and 1 protective factor.
The Clinical and Serological Findings in Patients with Toxocariasis in Korea
Sungjin Choi, MD, Taehoon Yim, MD, and Kyungho Yang, MD. Allergy and Rheumatology, Sunlin Hospital, Pohang, South Korea. Background: We performed this study to investigate the clinical and serological characteristics of human toxocariasis in Korea. Methods: Total 152 patients with peripheral eosinophilia (.450 cells/mL) were enrolled and they were divided into 2 groups based on a Toxocara excretory-secretory IgG ELISA: 95 seropositive patients and 57 seronegative patients. We not only compared the clinical features including age, sex, tissue infiltration of eosinophil and presence of allergic asthma and rhinitis but also serologic markers such as serum total IgE, specific IgE to Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farine (Df) by using immunoCAP between 2 groups. Results: The seropositive rate of toxocara was 62.5% (95/152) in the patients with peripheral eosinophilia in whom seropositive patients were older than seronegative patients (P ¼ 0.043), men were more than women (P , 0.01). The serum total eosinophils (P ¼ 0.048), total IgE level (P , 0.01) and the Df seropositive (immunoCAP .0.35 KU/L) rate (P , 0.01) were significantly higher in sereopositive patients than seronegative patients. The eosinophilic tissue infiltration in liver (P ¼ 0.003) or lung (P , 0.01) and ingestion of raw cow meat or liver (P , 0.01) were observed more frequently in seropositive patients but the presence of allergic asthma (P , 0.01) and rhinitis (P , 0.01) more frequnetly in seronegative patients. Among seropositive patients, there were positive correlations between the serum total IgE level, total eosinophils and the value of toxocara IgG ELISA OD (r ¼ 0.502, P , 0.01; r ¼ 0.247, P ¼ 0.016, respectively) and the specific IgE to Df was significantly higher (P , 0.01) than that to Dp suggesting there might be cross reaction between the antigen of Df and toxocara antigen. Conclusions: The ingestion of raw cow meat or liver was closely related to an increased risk of toxocariasis in Korea. We thought that the patients who had highly elevated serum total IgE level, peripheral eosinophilia and experience of ingestion of raw cow meat or liver but not allergic disease might have human toxocariasis so should be evaluated whether eosinophils were infiltrated in organs such as liver or lung.
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Interferon-Gamma Release AssaydUseful Tool for the Diagnosis of Pleural Tuberculosis
Andrea Ondrejkova, 1 and Gustav Ondrejka, MD 2 . 1 Laboratory of Immunology and Serology, PR LAB Novy Jicin, Novy Jicin, Czech Republic; 2 Department of Pulmonary Medicine, Hospital Novy Jicin, Novy Jicin, Czech Republic. Background: Pleural tuberculosis represents a big problem to diagnose despite of many diagnostic tools. CD41T-lymphocytes play an imprortant role in immune response against Mycobacterium tuberculosis. They are accumulated in pleural space affected with Mycobacterium tuberculosis and release an inflammatory cytokines (interferon-g, interleukin-2). These cytokines interact with macrophages to stimulate effective antimycobacterial actions. The pleural fluid lymphocytes and interferon-g level are elevated in many cases such as viral infections, malignancy or tuberculosis. We decided to evaluate a benefit of utilization of antigen specific Interferon-gamma release assay (IGRA) in pleural effusion (PE) to the diagnostics of pleural tuberculosis. Methods: We present results of 29 patients with lymphocytic PE of unknown cause. The total leukocytes count, lymfocyte subsets by flow cytometry with monoclonal antibodies directed against the T-lymphocyte antigens (CD3, CD4, CD8) and HLA DR antigen as a marker of T-lymphocyte activation were determined in PE. IGRA test was used to determine a level of specific interferon-gamma in PE and in whole blood too. Furthermore we analysed results of tuberculin skin test and Mycobacterium tuberculosis cultivation in the sputum and in PE. Results: Of the 29 lymphocytic PE was IGRA test positive in 3 cases (10,3%). These patients had the pleural effusion with activated CD4 1 Tlymphocytes predominance, elevated CD4/CD8 ratio. Mycobacterium tuberculosis cultivation was negative in both sputum and pleural fluid except 1 patient with positive sputum culture. The tuberculin skin test was higher than 15 mm of all 3 patients. The clinical diagnosis of active pleural tuberculosis was confirmed in these patients. AntiTB treatment was successful of all them. Lymphocytic PE with negative IGRA test was in 26 patients (89,7%): malignancy in 7, heart failure effusion in 3, parapneumonic effusion in 8 and other pathological causes was in 8 patients. Conclusions: Our results acknowledge that IGRA test applied to pleural fluid is very helpful to the diagnostics of pleural tuberculosis because the pleural fluid interferon-g level is measured after stimulation of T-lymphocytes by tuberculous specific antigens. We conclude that another important benefit of interferon-g release assays is the differential diagnostics of CD41T-lymphocytic pleural effusions.
